The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M HNSCC
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
All eligible patients will be equally randomized between the 2 following treatment groups: Standard treatment group: Camrelizumab 200mg IV every 2 weeks. Experimental group: Stereotactic body radiotherapy 27Gy/3F and Camrelizumab 200mg IV every 2 weeks.
All eligible patients will be equally randomized between the 2 following treatment groups: Standard treatment group: Camrelizumab 200mg IV every 2 weeks. Experimental group: Stereotactic body radiotherapy 27Gy/3F and Camrelizumab 200mg IV every 2 weeks.
Tracking Information
- NCT #
- NCT04830267
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Ying Wang, Ph.D, M.D. Chongqing University Cancer Hospital
Get Well Soon